Loading company
Kardigan, Inc.
KARD · Nasdaq · ·
Next earnings: November 10, 2026
$14.70-0.7%Sep 29 close
- 1M
- -26.6%
KARD · Nasdaq · ·
Next earnings: November 10, 2026
$14.70-0.7%Sep 29 close
Kardigan, Inc. is scheduled to report next on November 10, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
From the company’s own 8-K filing.
Kardigan, Inc. has no earnings call transcript available.
“Our IPO has positioned Kardigan to advance a portfolio of late-stage cardiovascular programs to address diseases where patients urgently need better treatment options,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Led by a proven and experienced management team, Kardigan is reimagining cardiovascular drug discovery and development through an integrated approach that unites deep cardiovascular biology, real-world patient data, and advanced analytics to enable more precise, efficient, and informed development of novel therapies. The company is based in South San Francisco, California and Princeton, New Jersey. To learn more, visit Kardigan.bio .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Kardigan, Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.